The Biology of FH-II: How the CLCN2 Gene Drives Aldosterone

While most cases of Primary Aldosteronism (PA) happen by chance, Familial Hyperaldosteronism Type II (FH-II) is driven by a specific variation in your genetic code ^[1]. For decades, doctors knew FH-II existed because they saw PA running in families, but they didn’t know exactly why ^[2]. The discovery of pathogenic variants in the CLCN2 gene provided a concrete molecular explanation for a significant portion of early-onset familial cases ^[3][4].

The Adrenal “Engine”: How the CLCN2 Gene Works

Inside your adrenal glands, specifically in a layer called the zona glomerulosa, there are tiny channels that act like gatekeepers for the cell ^[1][5]. One of these is the ClC-2 chloride channel, which is controlled by the CLCN2 gene ^[6].

In a healthy cell, this channel is usually closed when the cell is at rest. However, in CLCN2-associated FH-II, a gain-of-function variant occurs ^[1]. This means the “gate” opens too easily. This leads to a specific biological chain reaction:

1. Chloride Exit: Because the gate is open, chloride (which carries a negative charge) rushes out of the cell ^[6][5].
2. Depolarization: As the negative charge leaves, the electrical balance of the cell changes—a process called depolarization ^[5].
3. Calcium Inflow: This electrical shift tricks the cell’s calcium channels into opening. Calcium then floods into the cell ^[7][5].
4. Aldosterone Production: Calcium is a major trigger for aldosterone production. It activates an enzyme called aldosterone synthase, which forces the cell to produce excess aldosterone, even when your body doesn’t need it ^[6][2].

How FH-II is Inherited

CLCN2-associated FH-II follows an autosomal dominant inheritance pattern ^[1]. This means:

• 50% Transmission Risk: If you have a confirmed heterozygous pathogenic variant, there is a 50% chance of passing that exact genetic marker on to each of your biological children ^[1].
• Sibling Risk: If one of your parents carries the variant, your siblings also have a 50% chance of carrying it.
• Variable Penetrance: Inheriting the genetic variant does not mean a person will inevitably develop severe PA. The age of onset and severity can vary widely, even within the same family.

The “De Novo” Exception

It is possible to have a pathogenic CLCN2 variant even if neither of your parents has it. These are called de novo variants—new genetic changes that occurred for the first time in you ^[1][2]. If your variant is de novo, the risk to your siblings is generally much lower.

Interpreting Your Diagnosis

A genetic test can return different results, and a genetics professional should always interpret them alongside your biochemical tests. A pathogenic or likely pathogenic variant confirms the diagnosis. However, a variant of uncertain significance (VUS) means the lab found a change, but there is not enough evidence to prove it causes disease; a VUS should not be used to direct treatment or screen family members.

CLCN2-associated disease is typically bilateral, meaning it affects both adrenal glands ^[2]. Because both glands are usually involved, the standard treatment is medication rather than surgery ^[3][2]. However, a genetic result does not entirely replace imaging or specialist evaluation; if surgery is seriously being considered, specialized testing is still required to confirm whether the aldosterone excess is coming from one or both glands ^[1][8].